Click on headlines below to download research

TG4010 and Pexa-Vec readouts to define 2019
Transgene | 30/11/2018

Late-stage clinical trial readouts in 2019 will be critical to Transgene’s immunoncology (IO) aspirations and, if positive, could further its position…

Combination strategy awaiting validation
Transgene | 19/11/2018

Transgene develops virus-based product candidates for use in oncology and infectious diseases. Its five clinical products are currently in seven clinical…

Near-term data to define long-term strategy
Transgene | 16/07/2018

Transgene develops virus-based product candidates for use in oncology and infectious diseases, its five clinical products are currently in 11 clinical…